Trials / Completed
CompletedNCT04925934
Study of VIB7734 for the Treatment of Moderate to Severely Active SLE
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 214 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of VIB7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus in approximately 195 participants. The study duration will be 48 weeks, with a safety follow-up through week 56.There will be 3 parallel arms - 2 active treatment and 1 placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VIB7734 | VIB7734 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2021-05-28
- Primary completion
- 2023-05-16
- Completion
- 2023-06-09
- First posted
- 2021-06-14
- Last updated
- 2024-07-23
- Results posted
- 2024-07-23
Locations
67 sites across 11 countries: United States, Argentina, Greece, India, Mexico, Poland, Russia, Serbia, Spain, Taiwan, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04925934. Inclusion in this directory is not an endorsement.